{"transactions":[{"id":750079,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41455,"kind":"person","name":"Swain Judith L","position":1,"cik":"0001413573","reported_name":"Swain Judith L","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-06-04T20:14:34.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":false,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":89312},"source":{"system":"sec-edgar","filing":"0001062822-26-000108","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000108/form4.xml","form_type":"4"}},{"id":750078,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41455,"kind":"person","name":"Swain Judith L","position":1,"cik":"0001413573","reported_name":"Swain Judith L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-04T20:14:34.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":true,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":174486,"source":{"system":"sec-edgar","filing":"0001062822-26-000108","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000108/form4.xml","form_type":"4"}},{"id":750072,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41454,"kind":"person","name":"Sullivan Diane E.","position":1,"cik":"0001968736","reported_name":"Sullivan Diane E.","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-06-04T20:13:55.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":false,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":89312},"source":{"system":"sec-edgar","filing":"0001062822-26-000107","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000107/form4.xml","form_type":"4"}},{"id":750071,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41454,"kind":"person","name":"Sullivan Diane E.","position":1,"cik":"0001968736","reported_name":"Sullivan Diane E.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-04T20:13:55.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":true,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":126122,"source":{"system":"sec-edgar","filing":"0001062822-26-000107","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000107/form4.xml","form_type":"4"}},{"id":750070,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41453,"kind":"person","name":"SOBECKI CHRISTOPHER J","position":1,"cik":"0001053892","reported_name":"SOBECKI CHRISTOPHER J","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-06-04T20:13:09.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":false,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":89312},"source":{"system":"sec-edgar","filing":"0001062822-26-000106","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000106/form4.xml","form_type":"4"}},{"id":750069,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41453,"kind":"person","name":"SOBECKI CHRISTOPHER J","position":1,"cik":"0001053892","reported_name":"SOBECKI CHRISTOPHER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-04T20:13:09.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":true,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":293177,"source":{"system":"sec-edgar","filing":"0001062822-26-000106","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000106/form4.xml","form_type":"4"}},{"id":750068,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41452,"kind":"person","name":"Cheung Ivan","position":1,"cik":"0002042690","reported_name":"Cheung Ivan","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-06-04T20:12:20.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":false,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":89312},"source":{"system":"sec-edgar","filing":"0001062822-26-000105","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000105/form4.xml","form_type":"4"}},{"id":750067,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41452,"kind":"person","name":"Cheung Ivan","position":1,"cik":"0002042690","reported_name":"Cheung Ivan","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-04T20:12:20.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":true,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":89312,"source":{"system":"sec-edgar","filing":"0001062822-26-000105","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000105/form4.xml","form_type":"4"}},{"id":750064,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41451,"kind":"person","name":"BARKER SAM L","position":1,"cik":"0001226877","reported_name":"BARKER SAM L","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-06-04T20:11:35.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":false,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":89312},"source":{"system":"sec-edgar","filing":"0001062822-26-000104","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000104/form4.xml","form_type":"4"}},{"id":750063,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41451,"kind":"person","name":"BARKER SAM L","position":1,"cik":"0001226877","reported_name":"BARKER SAM L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-04T20:11:35.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":true,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":213771,"source":{"system":"sec-edgar","filing":"0001062822-26-000104","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000104/form4.xml","form_type":"4"}},{"id":750066,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":35613,"kind":"person","name":"Amouyal Philippe","position":1,"cik":"0001376854","reported_name":"Amouyal Philippe","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-06-04T20:10:52.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":false,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":89312},"source":{"system":"sec-edgar","filing":"0001062822-26-000103","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000103/form4.xml","form_type":"4"}},{"id":750065,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":35613,"kind":"person","name":"Amouyal Philippe","position":1,"cik":"0001376854","reported_name":"Amouyal Philippe","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-04T20:10:52.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":true,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":374486,"source":{"system":"sec-edgar","filing":"0001062822-26-000103","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000103/form4.xml","form_type":"4"}},{"id":750062,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-06-04T20:09:59.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":false,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":89312},"source":{"system":"sec-edgar","filing":"0001062822-26-000102","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000102/form4.xml","form_type":"4"}},{"id":750061,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-04T20:09:59.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":true,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1995498,"source":{"system":"sec-edgar","filing":"0001062822-26-000102","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000102/form4.xml","form_type":"4"}},{"id":787346,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":37420,"kind":"person","name":"Artal Participations S.a r.l.","position":1,"cik":"0002048403","reported_name":"Artal Participations S.a r.l.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37421,"kind":"person","name":"Artal International S.C.A.","position":2,"cik":"0001218180","reported_name":"Artal International S.C.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37422,"kind":"person","name":"Artal International Management S.A.","position":3,"cik":"0001522131","reported_name":"Artal International Management S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37423,"kind":"person","name":"Artal Group S.A.","position":4,"cik":"0001053906","reported_name":"Artal Group S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37424,"kind":"person","name":"Westend S.A.","position":5,"cik":"0001283968","reported_name":"Westend S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37425,"kind":"person","name":"Stichting Administratiekantoor Westend","position":6,"cik":"0001460840","reported_name":"Stichting Administratiekantoor Westend","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37426,"kind":"person","name":"Wittouck Amaury","position":7,"cik":"0001841311","reported_name":"Wittouck Amaury","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2026-05-09T01:45:20.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":408434.7,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms of a Preferred Stock Purchase Agreement, dated as of January 29, 2026, Artal Participations S.a r.l. acquired an aggregate of 408,434.70 shares of Series B convertible preferred stock, $0.01 par value per share (the \"Preferred Stock\") of the Issuer at a price of $65.00 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\") upon receipt of shareholder approval and the satisfaction of certain other conditions (the \"Conditions\"); however, absent the satisfaction of such conditions, the shares were not convertible, and as such, the Preferred Stock was originally reported on Table I. On April 30, 2026, all Conditions were met, and the 408,434.70 shares of Preferred Stock became derivative securities and automatically converted into 20,421,735 shares of Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of a Preferred Stock Purchase Agreement, dated as of January 29, 2026, Artal Participations S.a r.l. acquired an aggregate of 408,434.70 shares of Series B convertible preferred stock, $0.01 par value per share (the \"Preferred Stock\") of the Issuer at a price of $65.00 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\") upon receipt of shareholder approval and the satisfaction of certain other conditions (the \"Conditions\"); however, absent the satisfaction of such conditions, the shares were not convertible, and as such, the Preferred Stock was originally reported on Table I. On April 30, 2026, all Conditions were met, and the 408,434.70 shares of Preferred Stock became derivative securities and automatically converted into 20,421,735 shares of Issuer Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of a Preferred Stock Purchase Agreement, dated as of January 29, 2026, Artal Participations S.a r.l. acquired an aggregate of 408,434.70 shares of Series B convertible preferred stock, $0.01 par value per share (the \"Preferred Stock\") of the Issuer at a price of $65.00 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\") upon receipt of shareholder approval and the satisfaction of certain other conditions (the \"Conditions\"); however, absent the satisfaction of such conditions, the shares were not convertible, and as such, the Preferred Stock was originally reported on Table I. On April 30, 2026, all Conditions were met, and the 408,434.70 shares of Preferred Stock became derivative securities and automatically converted into 20,421,735 shares of Issuer Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by Artal Participations S.a r.l."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the \"Stichting\"). Mr. Amaury Wittouck is the sole member of the board of the Stichting."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20421735},"source":{"system":"sec-edgar","filing":"0001193125-26-215297","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526215297/ownership.xml","form_type":"4"}},{"id":787345,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":37420,"kind":"person","name":"Artal Participations S.a r.l.","position":1,"cik":"0002048403","reported_name":"Artal Participations S.a r.l.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37421,"kind":"person","name":"Artal International S.C.A.","position":2,"cik":"0001218180","reported_name":"Artal International S.C.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37422,"kind":"person","name":"Artal International Management S.A.","position":3,"cik":"0001522131","reported_name":"Artal International Management S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37423,"kind":"person","name":"Artal Group S.A.","position":4,"cik":"0001053906","reported_name":"Artal Group S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37424,"kind":"person","name":"Westend S.A.","position":5,"cik":"0001283968","reported_name":"Westend S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37425,"kind":"person","name":"Stichting Administratiekantoor Westend","position":6,"cik":"0001460840","reported_name":"Stichting Administratiekantoor Westend","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37426,"kind":"person","name":"Wittouck Amaury","position":7,"cik":"0001841311","reported_name":"Wittouck Amaury","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2026-05-09T01:45:20.000Z","date":"2026-04-30","kind":"grant","planned":false,"acquired":true,"shares":408434.7,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms of a Preferred Stock Purchase Agreement, dated as of January 29, 2026, Artal Participations S.a r.l. acquired an aggregate of 408,434.70 shares of Series B convertible preferred stock, $0.01 par value per share (the \"Preferred Stock\") of the Issuer at a price of $65.00 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\") upon receipt of shareholder approval and the satisfaction of certain other conditions (the \"Conditions\"); however, absent the satisfaction of such conditions, the shares were not convertible, and as such, the Preferred Stock was originally reported on Table I. On April 30, 2026, all Conditions were met, and the 408,434.70 shares of Preferred Stock became derivative securities and automatically converted into 20,421,735 shares of Issuer Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of a Preferred Stock Purchase Agreement, dated as of January 29, 2026, Artal Participations S.a r.l. acquired an aggregate of 408,434.70 shares of Series B convertible preferred stock, $0.01 par value per share (the \"Preferred Stock\") of the Issuer at a price of $65.00 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\") upon receipt of shareholder approval and the satisfaction of certain other conditions (the \"Conditions\"); however, absent the satisfaction of such conditions, the shares were not convertible, and as such, the Preferred Stock was originally reported on Table I. On April 30, 2026, all Conditions were met, and the 408,434.70 shares of Preferred Stock became derivative securities and automatically converted into 20,421,735 shares of Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of a Preferred Stock Purchase Agreement, dated as of January 29, 2026, Artal Participations S.a r.l. acquired an aggregate of 408,434.70 shares of Series B convertible preferred stock, $0.01 par value per share (the \"Preferred Stock\") of the Issuer at a price of $65.00 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\") upon receipt of shareholder approval and the satisfaction of certain other conditions (the \"Conditions\"); however, absent the satisfaction of such conditions, the shares were not convertible, and as such, the Preferred Stock was originally reported on Table I. On April 30, 2026, all Conditions were met, and the 408,434.70 shares of Preferred Stock became derivative securities and automatically converted into 20,421,735 shares of Issuer Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of a Preferred Stock Purchase Agreement, dated as of January 29, 2026, Artal Participations S.a r.l. acquired an aggregate of 408,434.70 shares of Series B convertible preferred stock, $0.01 par value per share (the \"Preferred Stock\") of the Issuer at a price of $65.00 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\") upon receipt of shareholder approval and the satisfaction of certain other conditions (the \"Conditions\"); however, absent the satisfaction of such conditions, the shares were not convertible, and as such, the Preferred Stock was originally reported on Table I. On April 30, 2026, all Conditions were met, and the 408,434.70 shares of Preferred Stock became derivative securities and automatically converted into 20,421,735 shares of Issuer Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by Artal Participations S.a r.l."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the \"Stichting\"). Mr. Amaury Wittouck is the sole member of the board of the Stichting."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":408434.7,"derivative":{"underlying":"Common Stock","underlying_shares":20421735},"source":{"system":"sec-edgar","filing":"0001193125-26-215297","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526215297/ownership.xml","form_type":"4"}},{"id":787344,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":37420,"kind":"person","name":"Artal Participations S.a r.l.","position":1,"cik":"0002048403","reported_name":"Artal Participations S.a r.l.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37421,"kind":"person","name":"Artal International S.C.A.","position":2,"cik":"0001218180","reported_name":"Artal International S.C.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37422,"kind":"person","name":"Artal International Management S.A.","position":3,"cik":"0001522131","reported_name":"Artal International Management S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37423,"kind":"person","name":"Artal Group S.A.","position":4,"cik":"0001053906","reported_name":"Artal Group S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37424,"kind":"person","name":"Westend S.A.","position":5,"cik":"0001283968","reported_name":"Westend S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37425,"kind":"person","name":"Stichting Administratiekantoor Westend","position":6,"cik":"0001460840","reported_name":"Stichting Administratiekantoor Westend","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37426,"kind":"person","name":"Wittouck Amaury","position":7,"cik":"0001841311","reported_name":"Wittouck Amaury","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-09T01:45:20.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":20421735,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of a Preferred Stock Purchase Agreement, dated as of January 29, 2026, Artal Participations S.a r.l. acquired an aggregate of 408,434.70 shares of Series B convertible preferred stock, $0.01 par value per share (the \"Preferred Stock\") of the Issuer at a price of $65.00 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\") upon receipt of shareholder approval and the satisfaction of certain other conditions (the \"Conditions\"); however, absent the satisfaction of such conditions, the shares were not convertible, and as such, the Preferred Stock was originally reported on Table I. On April 30, 2026, all Conditions were met, and the 408,434.70 shares of Preferred Stock became derivative securities and automatically converted into 20,421,735 shares of Issuer Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by Artal Participations S.a r.l."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the \"Stichting\"). Mr. Amaury Wittouck is the sole member of the board of the Stichting."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":175156062,"source":{"system":"sec-edgar","filing":"0001193125-26-215297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526215297/ownership.xml","form_type":"4"}},{"id":794411,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":35613,"kind":"person","name":"Amouyal Philippe","position":1,"cik":"0001376854","reported_name":"Amouyal Philippe","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T20:59:21.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":43478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":43478,"derivative":{"exercise_price":1.61,"expiration_date":"2036-05-01","underlying":"Common Stock","underlying_shares":43478},"source":{"system":"sec-edgar","filing":"0001062822-26-000092","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000092/form4.xml","form_type":"4"}},{"id":794410,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":35613,"kind":"person","name":"Amouyal Philippe","position":1,"cik":"0001376854","reported_name":"Amouyal Philippe","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-05-04T20:59:21.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":35714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":35714,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":35714},"source":{"system":"sec-edgar","filing":"0001062822-26-000092","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000092/form4.xml","form_type":"4"}},{"id":794413,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41453,"kind":"person","name":"SOBECKI CHRISTOPHER J","position":1,"cik":"0001053892","reported_name":"SOBECKI CHRISTOPHER J","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T20:57:03.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":43478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":43478,"derivative":{"exercise_price":1.61,"expiration_date":"2036-05-01","underlying":"Common Stock","underlying_shares":43478},"source":{"system":"sec-edgar","filing":"0001062822-26-000090","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000090/form4.xml","form_type":"4"}},{"id":794412,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41453,"kind":"person","name":"SOBECKI CHRISTOPHER J","position":1,"cik":"0001053892","reported_name":"SOBECKI CHRISTOPHER J","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-05-04T20:57:03.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":35714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":35714,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":35714},"source":{"system":"sec-edgar","filing":"0001062822-26-000090","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000090/form4.xml","form_type":"4"}},{"id":794409,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41451,"kind":"person","name":"BARKER SAM L","position":1,"cik":"0001226877","reported_name":"BARKER SAM L","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T20:32:01.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":43478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":43478,"derivative":{"exercise_price":1.61,"expiration_date":"2036-05-01","underlying":"Common Stock","underlying_shares":43478},"source":{"system":"sec-edgar","filing":"0001062822-26-000084","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000084/form4.xml","form_type":"4"}},{"id":794408,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41451,"kind":"person","name":"BARKER SAM L","position":1,"cik":"0001226877","reported_name":"BARKER SAM L","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-05-04T20:32:01.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":35714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":35714,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":35714},"source":{"system":"sec-edgar","filing":"0001062822-26-000084","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000084/form4.xml","form_type":"4"}},{"id":794407,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41452,"kind":"person","name":"Cheung Ivan","position":1,"cik":"0002042690","reported_name":"Cheung Ivan","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T20:30:13.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":43478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":43478,"derivative":{"exercise_price":1.61,"expiration_date":"2036-05-01","underlying":"Common Stock","underlying_shares":43478},"source":{"system":"sec-edgar","filing":"0001062822-26-000082","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000082/form4.xml","form_type":"4"}},{"id":794406,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41452,"kind":"person","name":"Cheung Ivan","position":1,"cik":"0002042690","reported_name":"Cheung Ivan","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-05-04T20:30:13.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":35714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":35714,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":35714},"source":{"system":"sec-edgar","filing":"0001062822-26-000082","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000082/form4.xml","form_type":"4"}},{"id":794405,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41455,"kind":"person","name":"Swain Judith L","position":1,"cik":"0001413573","reported_name":"Swain Judith L","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T20:27:49.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":43478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":43478,"derivative":{"exercise_price":1.61,"expiration_date":"2036-05-01","underlying":"Common Stock","underlying_shares":43478},"source":{"system":"sec-edgar","filing":"0001062822-26-000080","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000080/form4.xml","form_type":"4"}},{"id":794404,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41455,"kind":"person","name":"Swain Judith L","position":1,"cik":"0001413573","reported_name":"Swain Judith L","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-05-04T20:27:49.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":35714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":35714,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":35714},"source":{"system":"sec-edgar","filing":"0001062822-26-000080","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000080/form4.xml","form_type":"4"}},{"id":794401,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41454,"kind":"person","name":"Sullivan Diane E.","position":1,"cik":"0001968736","reported_name":"Sullivan Diane E.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T20:20:08.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":43478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":43478,"derivative":{"exercise_price":1.61,"expiration_date":"2036-05-01","underlying":"Common Stock","underlying_shares":43478},"source":{"system":"sec-edgar","filing":"0001062822-26-000075","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000075/form4.xml","form_type":"4"}},{"id":794400,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41454,"kind":"person","name":"Sullivan Diane E.","position":1,"cik":"0001968736","reported_name":"Sullivan Diane E.","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-05-04T20:20:08.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":35714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":35714,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":35714},"source":{"system":"sec-edgar","filing":"0001062822-26-000075","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000075/form4.xml","form_type":"4"}},{"id":794403,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T20:09:37.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":43478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":43478,"derivative":{"exercise_price":1.61,"expiration_date":"2036-05-01","underlying":"Common Stock","underlying_shares":43478},"source":{"system":"sec-edgar","filing":"0001062822-26-000067","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000067/form4.xml","form_type":"4"}},{"id":794402,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-05-04T20:09:37.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":35714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":35714,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":35714},"source":{"system":"sec-edgar","filing":"0001062822-26-000067","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000067/form4.xml","form_type":"4"}},{"id":870009,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63547,"kind":"person","name":"McDermott Wendy","position":1,"cik":"0001902760","reported_name":"McDermott Wendy","relationship":{"officer":true,"officer_title":"SVP, Human Resources"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:20:59.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":144393,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":288787,"derivative":{"underlying":"Common Stock","underlying_shares":144393},"source":{"system":"sec-edgar","filing":"0001062822-26-000041","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000041/form4.xml","form_type":"4"}},{"id":870008,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63547,"kind":"person","name":"McDermott Wendy","position":1,"cik":"0001902760","reported_name":"McDermott Wendy","relationship":{"officer":true,"officer_title":"SVP, Human Resources"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:20:59.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":52316,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":52317,"derivative":{"underlying":"Common Stock","underlying_shares":52316},"source":{"system":"sec-edgar","filing":"0001062822-26-000041","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000041/form4.xml","form_type":"4"}},{"id":870007,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63547,"kind":"person","name":"McDermott Wendy","position":1,"cik":"0001902760","reported_name":"McDermott Wendy","relationship":{"officer":true,"officer_title":"SVP, Human Resources"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:20:59.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":27697,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":27697},"source":{"system":"sec-edgar","filing":"0001062822-26-000041","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000041/form4.xml","form_type":"4"}},{"id":870006,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63547,"kind":"person","name":"McDermott Wendy","position":1,"cik":"0001902760","reported_name":"McDermott Wendy","relationship":{"officer":true,"officer_title":"SVP, Human Resources"}}],"security":"Common Stock","published_at":"2026-03-03T12:20:59.000Z","date":"2026-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":68107,"price":1.47,"value":100117.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":277945,"source":{"system":"sec-edgar","filing":"0001062822-26-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000041/form4.xml","form_type":"4"}},{"id":870005,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63547,"kind":"person","name":"McDermott Wendy","position":1,"cik":"0001902760","reported_name":"McDermott Wendy","relationship":{"officer":true,"officer_title":"SVP, Human Resources"}}],"security":"Common Stock","published_at":"2026-03-03T12:20:59.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":144393,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":346052,"source":{"system":"sec-edgar","filing":"0001062822-26-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000041/form4.xml","form_type":"4"}},{"id":870004,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63547,"kind":"person","name":"McDermott Wendy","position":1,"cik":"0001902760","reported_name":"McDermott Wendy","relationship":{"officer":true,"officer_title":"SVP, Human Resources"}}],"security":"Common Stock","published_at":"2026-03-03T12:20:59.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":52316,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":201659,"source":{"system":"sec-edgar","filing":"0001062822-26-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000041/form4.xml","form_type":"4"}},{"id":870003,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63547,"kind":"person","name":"McDermott Wendy","position":1,"cik":"0001902760","reported_name":"McDermott Wendy","relationship":{"officer":true,"officer_title":"SVP, Human Resources"}}],"security":"Common Stock","published_at":"2026-03-03T12:20:59.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":27697,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":149343,"source":{"system":"sec-edgar","filing":"0001062822-26-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000041/form4.xml","form_type":"4"}},{"id":870002,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63546,"kind":"person","name":"Martens Rachel Yap","position":1,"cik":"0002071589","reported_name":"Martens Rachel Yap","relationship":{"officer":true,"officer_title":"SVP, Partnerships & Corp Strat"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:20:20.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":67090,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":134180,"derivative":{"underlying":"Common Stock","underlying_shares":67090},"source":{"system":"sec-edgar","filing":"0001062822-26-000040","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000040/form4.xml","form_type":"4"}},{"id":870001,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63546,"kind":"person","name":"Martens Rachel Yap","position":1,"cik":"0002071589","reported_name":"Martens Rachel Yap","relationship":{"officer":true,"officer_title":"SVP, Partnerships & Corp Strat"}}],"security":"Common Stock","published_at":"2026-03-03T12:20:20.000Z","date":"2026-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":35826,"price":1.47,"value":52664.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":31264,"source":{"system":"sec-edgar","filing":"0001062822-26-000040","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000040/form4.xml","form_type":"4"}},{"id":870000,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63546,"kind":"person","name":"Martens Rachel Yap","position":1,"cik":"0002071589","reported_name":"Martens Rachel Yap","relationship":{"officer":true,"officer_title":"SVP, Partnerships & Corp Strat"}}],"security":"Common Stock","published_at":"2026-03-03T12:20:20.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":67090,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":67090,"source":{"system":"sec-edgar","filing":"0001062822-26-000040","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000040/form4.xml","form_type":"4"}},{"id":869999,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63545,"kind":"person","name":"Granowitz Craig B","position":1,"cik":"0001876655","reported_name":"Granowitz Craig B","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:19:33.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":202260,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":404520,"derivative":{"underlying":"Common Stock","underlying_shares":202260},"source":{"system":"sec-edgar","filing":"0001062822-26-000039","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000039/form4.xml","form_type":"4"}},{"id":869998,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63545,"kind":"person","name":"Granowitz Craig B","position":1,"cik":"0001876655","reported_name":"Granowitz Craig B","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:19:33.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":74226,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":74227,"derivative":{"underlying":"Common Stock","underlying_shares":74226},"source":{"system":"sec-edgar","filing":"0001062822-26-000039","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000039/form4.xml","form_type":"4"}},{"id":869997,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63545,"kind":"person","name":"Granowitz Craig B","position":1,"cik":"0001876655","reported_name":"Granowitz Craig B","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:19:33.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":35790,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":35790},"source":{"system":"sec-edgar","filing":"0001062822-26-000039","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000039/form4.xml","form_type":"4"}},{"id":869996,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63545,"kind":"person","name":"Granowitz Craig B","position":1,"cik":"0001876655","reported_name":"Granowitz Craig B","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T12:19:33.000Z","date":"2026-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":109098,"price":1.47,"value":160374.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":323430,"source":{"system":"sec-edgar","filing":"0001062822-26-000039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000039/form4.xml","form_type":"4"}},{"id":869995,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63545,"kind":"person","name":"Granowitz Craig B","position":1,"cik":"0001876655","reported_name":"Granowitz Craig B","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T12:19:33.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":202260,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":432528,"source":{"system":"sec-edgar","filing":"0001062822-26-000039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000039/form4.xml","form_type":"4"}},{"id":869994,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63545,"kind":"person","name":"Granowitz Craig B","position":1,"cik":"0001876655","reported_name":"Granowitz Craig B","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T12:19:33.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":74226,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":230268,"source":{"system":"sec-edgar","filing":"0001062822-26-000039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000039/form4.xml","form_type":"4"}},{"id":869993,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63545,"kind":"person","name":"Granowitz Craig B","position":1,"cik":"0001876655","reported_name":"Granowitz Craig B","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T12:19:33.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":35790,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":156042,"source":{"system":"sec-edgar","filing":"0001062822-26-000039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000039/form4.xml","form_type":"4"}},{"id":869987,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63543,"kind":"person","name":"Gopinathan Suma","position":1,"cik":"0002071581","reported_name":"Gopinathan Suma","relationship":{"officer":true,"officer_title":"SVP, Discovery"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:18:43.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":65640,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":131280,"derivative":{"underlying":"Common Stock","underlying_shares":65640},"source":{"system":"sec-edgar","filing":"0001062822-26-000038","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000038/form4.xml","form_type":"4"}},{"id":869986,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63543,"kind":"person","name":"Gopinathan Suma","position":1,"cik":"0002071581","reported_name":"Gopinathan Suma","relationship":{"officer":true,"officer_title":"SVP, Discovery"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:18:43.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":20310,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":20310,"derivative":{"underlying":"Common Stock","underlying_shares":20310},"source":{"system":"sec-edgar","filing":"0001062822-26-000038","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000038/form4.xml","form_type":"4"}},{"id":869985,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63543,"kind":"person","name":"Gopinathan Suma","position":1,"cik":"0002071581","reported_name":"Gopinathan Suma","relationship":{"officer":true,"officer_title":"SVP, Discovery"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:18:43.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":14000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001062822-26-000038","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000038/form4.xml","form_type":"4"}},{"id":869984,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63543,"kind":"person","name":"Gopinathan Suma","position":1,"cik":"0002071581","reported_name":"Gopinathan Suma","relationship":{"officer":true,"officer_title":"SVP, Discovery"}}],"security":"Common Stock","published_at":"2026-03-03T12:18:43.000Z","date":"2026-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":24338,"price":1.47,"value":35776.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":150132,"source":{"system":"sec-edgar","filing":"0001062822-26-000038","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000038/form4.xml","form_type":"4"}},{"id":869983,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63543,"kind":"person","name":"Gopinathan Suma","position":1,"cik":"0002071581","reported_name":"Gopinathan Suma","relationship":{"officer":true,"officer_title":"SVP, Discovery"}}],"security":"Common Stock","published_at":"2026-03-03T12:18:43.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":65640,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":174470,"source":{"system":"sec-edgar","filing":"0001062822-26-000038","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000038/form4.xml","form_type":"4"}},{"id":869982,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63543,"kind":"person","name":"Gopinathan Suma","position":1,"cik":"0002071581","reported_name":"Gopinathan Suma","relationship":{"officer":true,"officer_title":"SVP, Discovery"}}],"security":"Common Stock","published_at":"2026-03-03T12:18:43.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":20310,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":108830,"source":{"system":"sec-edgar","filing":"0001062822-26-000038","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000038/form4.xml","form_type":"4"}},{"id":869981,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63543,"kind":"person","name":"Gopinathan Suma","position":1,"cik":"0002071581","reported_name":"Gopinathan Suma","relationship":{"officer":true,"officer_title":"SVP, Discovery"}}],"security":"Common Stock","published_at":"2026-03-03T12:18:43.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":14000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":88520,"source":{"system":"sec-edgar","filing":"0001062822-26-000038","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000038/form4.xml","form_type":"4"}},{"id":869992,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63544,"kind":"person","name":"DeFrancesco Lisa","position":1,"cik":"0001846325","reported_name":"DeFrancesco Lisa","relationship":{"officer":true,"officer_title":"SVP, IR and Corp Comm"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:18:00.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":128190,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":256380,"derivative":{"underlying":"Common Stock","underlying_shares":128190},"source":{"system":"sec-edgar","filing":"0001062822-26-000037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000037/form4.xml","form_type":"4"}},{"id":869991,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63544,"kind":"person","name":"DeFrancesco Lisa","position":1,"cik":"0001846325","reported_name":"DeFrancesco Lisa","relationship":{"officer":true,"officer_title":"SVP, IR and Corp Comm"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:18:00.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":24674,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":24673,"derivative":{"underlying":"Common Stock","underlying_shares":24674},"source":{"system":"sec-edgar","filing":"0001062822-26-000037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000037/form4.xml","form_type":"4"}},{"id":869990,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63544,"kind":"person","name":"DeFrancesco Lisa","position":1,"cik":"0001846325","reported_name":"DeFrancesco Lisa","relationship":{"officer":true,"officer_title":"SVP, IR and Corp Comm"}}],"security":"Common Stock","published_at":"2026-03-03T12:18:00.000Z","date":"2026-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":74572,"price":1.47,"value":109620.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":93869,"source":{"system":"sec-edgar","filing":"0001062822-26-000037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000037/form4.xml","form_type":"4"}},{"id":869989,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63544,"kind":"person","name":"DeFrancesco Lisa","position":1,"cik":"0001846325","reported_name":"DeFrancesco Lisa","relationship":{"officer":true,"officer_title":"SVP, IR and Corp Comm"}}],"security":"Common Stock","published_at":"2026-03-03T12:18:00.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":128190,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":168441,"source":{"system":"sec-edgar","filing":"0001062822-26-000037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000037/form4.xml","form_type":"4"}},{"id":869988,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63544,"kind":"person","name":"DeFrancesco Lisa","position":1,"cik":"0001846325","reported_name":"DeFrancesco Lisa","relationship":{"officer":true,"officer_title":"SVP, IR and Corp Comm"}}],"security":"Common Stock","published_at":"2026-03-03T12:18:00.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":24674,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":40251,"source":{"system":"sec-edgar","filing":"0001062822-26-000037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000037/form4.xml","form_type":"4"}},{"id":869980,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63542,"kind":"person","name":"Crum Brian T","position":1,"cik":"0001792747","reported_name":"Crum Brian T","relationship":{"officer":true,"officer_title":"SVP, General Counsel & Secr."}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:17:13.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":170163,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":340327,"derivative":{"underlying":"Common Stock","underlying_shares":170163},"source":{"system":"sec-edgar","filing":"0001062822-26-000036","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000036/form4.xml","form_type":"4"}},{"id":869979,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63542,"kind":"person","name":"Crum Brian T","position":1,"cik":"0001792747","reported_name":"Crum Brian T","relationship":{"officer":true,"officer_title":"SVP, General Counsel & Secr."}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:17:13.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":33457,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":33457},"source":{"system":"sec-edgar","filing":"0001062822-26-000036","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000036/form4.xml","form_type":"4"}},{"id":869978,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63542,"kind":"person","name":"Crum Brian T","position":1,"cik":"0001792747","reported_name":"Crum Brian T","relationship":{"officer":true,"officer_title":"SVP, General Counsel & Secr."}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:17:13.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":69386,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":69387,"derivative":{"underlying":"Common Stock","underlying_shares":69386},"source":{"system":"sec-edgar","filing":"0001062822-26-000036","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000036/form4.xml","form_type":"4"}},{"id":869977,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63542,"kind":"person","name":"Crum Brian T","position":1,"cik":"0001792747","reported_name":"Crum Brian T","relationship":{"officer":true,"officer_title":"SVP, General Counsel & Secr."}}],"security":"Common Stock","published_at":"2026-03-03T12:17:13.000Z","date":"2026-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":105019,"price":1.47,"value":154377.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":428802,"source":{"system":"sec-edgar","filing":"0001062822-26-000036","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000036/form4.xml","form_type":"4"}},{"id":869976,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63542,"kind":"person","name":"Crum Brian T","position":1,"cik":"0001792747","reported_name":"Crum Brian T","relationship":{"officer":true,"officer_title":"SVP, General Counsel & Secr."}}],"security":"Common Stock","published_at":"2026-03-03T12:17:13.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":170163,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":533821,"source":{"system":"sec-edgar","filing":"0001062822-26-000036","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000036/form4.xml","form_type":"4"}},{"id":869975,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63542,"kind":"person","name":"Crum Brian T","position":1,"cik":"0001792747","reported_name":"Crum Brian T","relationship":{"officer":true,"officer_title":"SVP, General Counsel & Secr."}}],"security":"Common Stock","published_at":"2026-03-03T12:17:13.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":69386,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":330201,"source":{"system":"sec-edgar","filing":"0001062822-26-000036","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000036/form4.xml","form_type":"4"}},{"id":869974,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63542,"kind":"person","name":"Crum Brian T","position":1,"cik":"0001792747","reported_name":"Crum Brian T","relationship":{"officer":true,"officer_title":"SVP, General Counsel & Secr."}}],"security":"Common Stock","published_at":"2026-03-03T12:17:13.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":33457,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":363658,"source":{"system":"sec-edgar","filing":"0001062822-26-000036","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000036/form4.xml","form_type":"4"}},{"id":869973,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:16:31.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":160237,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":320473,"derivative":{"underlying":"Common Stock","underlying_shares":160237},"source":{"system":"sec-edgar","filing":"0001062822-26-000035","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000035/form4.xml","form_type":"4"}},{"id":869972,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T12:16:31.000Z","date":"2026-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":54881,"price":1.47,"value":80675.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":105356,"source":{"system":"sec-edgar","filing":"0001062822-26-000035","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000035/form4.xml","form_type":"4"}},{"id":869971,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T12:16:31.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":160237,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":160237,"source":{"system":"sec-edgar","filing":"0001062822-26-000035","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000035/form4.xml","form_type":"4"}},{"id":869970,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63540,"kind":"person","name":"Exton Michael","position":1,"cik":"0002029249","reported_name":"Exton Michael","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:15:34.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":503263,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":1006527,"derivative":{"underlying":"Common Stock","underlying_shares":503263},"source":{"system":"sec-edgar","filing":"0001062822-26-000034","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000034/form4.xml","form_type":"4"}},{"id":869969,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63540,"kind":"person","name":"Exton Michael","position":1,"cik":"0002029249","reported_name":"Exton Michael","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-03T12:15:34.000Z","date":"2026-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":204831,"price":1.47,"value":301101.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":298432,"source":{"system":"sec-edgar","filing":"0001062822-26-000034","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000034/form4.xml","form_type":"4"}},{"id":869968,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63540,"kind":"person","name":"Exton Michael","position":1,"cik":"0002029249","reported_name":"Exton Michael","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-03T12:15:34.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":503263,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":503263,"source":{"system":"sec-edgar","filing":"0001062822-26-000034","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000034/form4.xml","form_type":"4"}},{"id":878062,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-27T13:33:21.000Z","date":"2026-02-25","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":1.49,"value":2980.0,"ownership":{"direct":true},"balance_after":1906186,"source":{"system":"sec-edgar","filing":"0001062822-26-000033","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000033/form4.xml","form_type":"4"}},{"id":882470,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-25T12:00:27.000Z","date":"2026-02-23","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":1.47,"value":147000.0,"ownership":{"direct":true},"balance_after":1904186,"source":{"system":"sec-edgar","filing":"0001062822-26-000032","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000032/form4.xml","form_type":"4"}},{"id":888826,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-23T12:49:43.000Z","date":"2026-02-20","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":1.4779,"value":147790.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.49 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":1804186,"source":{"system":"sec-edgar","filing":"0001062822-26-000031","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000031/form4.xml","form_type":"4"}},{"id":888825,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-23T12:49:43.000Z","date":"2026-02-19","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":1.4393,"value":71965.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.425 to $1.455 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":1704186,"source":{"system":"sec-edgar","filing":"0001062822-26-000031","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000031/form4.xml","form_type":"4"}},{"id":894324,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":37420,"kind":"person","name":"Artal Participations S.a r.l.","position":1,"cik":"0002048403","reported_name":"Artal Participations S.a r.l.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37421,"kind":"person","name":"Artal International S.C.A.","position":2,"cik":"0001218180","reported_name":"Artal International S.C.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37422,"kind":"person","name":"Artal International Management S.A.","position":3,"cik":"0001522131","reported_name":"Artal International Management S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37423,"kind":"person","name":"Artal Group S.A.","position":4,"cik":"0001053906","reported_name":"Artal Group S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37424,"kind":"person","name":"Westend S.A.","position":5,"cik":"0001283968","reported_name":"Westend S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37425,"kind":"person","name":"Stichting Administratiekantoor Westend","position":6,"cik":"0001460840","reported_name":"Stichting Administratiekantoor Westend","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37426,"kind":"person","name":"Wittouck Amaury","position":7,"cik":"0001841311","reported_name":"Wittouck Amaury","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2026-02-19T21:50:12.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":41289.58,"price":65,"value":2683822.7,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to that certain preferred stock purchase agreement (the \"Purchase Agreement\") with the Issuer, dated as of January 29, 2026, in connection with the underwriter's partial exercise of their option to purchase additional shares of Issuer common stock par value $0.001 per share (the \"Common Stock\") in an underwritten public offering, Artal Participations S.a r.l. purchased an additional 41,289.58 shares of Issuer Series B Convertible Preferred Stock, par value $0.01 per share (the \"Preferred Stock\") at a price of $65.00 per share. Each share of Preferred Stock will automatically convert into 50 shares of Common Stock upon receipt of shareholder approval and the satisfaction of certain other conditions; however, absent the satisfaction of such conditions, the shares are not convertible."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by Artal Participations S.a r.l."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the \"Stichting\"). Mr. Amaury Wittouck is the sole member of the board of the Stichting."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":408434.7,"source":{"system":"sec-edgar","filing":"0001193125-26-059599","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526059599/ownership.xml","form_type":"4"}},{"id":898143,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-18T21:30:52.000Z","date":"2026-02-18","kind":"purchase","planned":false,"acquired":true,"shares":133688,"price":1.32,"value":176468.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.315 to $1.32 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":1654186,"source":{"system":"sec-edgar","filing":"0001062822-26-000029","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000029/form4.xml","form_type":"4"}},{"id":898142,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-18T21:30:52.000Z","date":"2026-02-17","kind":"purchase","planned":false,"acquired":true,"shares":76857,"price":1.3082,"value":100544.3274,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.295 to $1.31 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":1520498,"source":{"system":"sec-edgar","filing":"0001062822-26-000029","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000029/form4.xml","form_type":"4"}},{"id":898141,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-18T21:30:52.000Z","date":"2026-02-13","kind":"purchase","planned":false,"acquired":true,"shares":57952,"price":1.3093,"value":75876.5536,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.31 per share.  The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":1443641,"source":{"system":"sec-edgar","filing":"0001062822-26-000029","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000029/form4.xml","form_type":"4"}},{"id":901916,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63547,"kind":"person","name":"McDermott Wendy","position":1,"cik":"0001902760","reported_name":"McDermott Wendy","relationship":{"officer":true,"officer_title":"SVP, Human Resources"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-17T21:10:59.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":375300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":375300,"derivative":{"exercise_price":1.37,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":375300},"source":{"system":"sec-edgar","filing":"0001062822-26-000026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000026/form4.xml","form_type":"4"}},{"id":901915,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63547,"kind":"person","name":"McDermott Wendy","position":1,"cik":"0001902760","reported_name":"McDermott Wendy","relationship":{"officer":true,"officer_title":"SVP, Human Resources"}}],"security":"Restricted Stock Units","published_at":"2026-02-17T21:10:59.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":250200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":250200,"derivative":{"underlying":"Common Stock","underlying_shares":250200},"source":{"system":"sec-edgar","filing":"0001062822-26-000026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000026/form4.xml","form_type":"4"}},{"id":901914,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63546,"kind":"person","name":"Martens Rachel Yap","position":1,"cik":"0002071589","reported_name":"Martens Rachel Yap","relationship":{"officer":true,"officer_title":"SVP, Partnerships & Corp Strat"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-17T21:10:18.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":290620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":290620,"derivative":{"exercise_price":1.37,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":290620},"source":{"system":"sec-edgar","filing":"0001062822-26-000025","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000025/form4.xml","form_type":"4"}},{"id":901913,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63546,"kind":"person","name":"Martens Rachel Yap","position":1,"cik":"0002071589","reported_name":"Martens Rachel Yap","relationship":{"officer":true,"officer_title":"SVP, Partnerships & Corp Strat"}}],"security":"Restricted Stock Units","published_at":"2026-02-17T21:10:18.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":193740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":193740,"derivative":{"underlying":"Common Stock","underlying_shares":193740},"source":{"system":"sec-edgar","filing":"0001062822-26-000025","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000025/form4.xml","form_type":"4"}},{"id":901912,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63545,"kind":"person","name":"Granowitz Craig B","position":1,"cik":"0001876655","reported_name":"Granowitz Craig B","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-17T21:09:31.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":519920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":519920,"derivative":{"exercise_price":1.37,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":519920},"source":{"system":"sec-edgar","filing":"0001062822-26-000024","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000024/form4.xml","form_type":"4"}},{"id":901911,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63545,"kind":"person","name":"Granowitz Craig B","position":1,"cik":"0001876655","reported_name":"Granowitz Craig B","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-17T21:09:31.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":346610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":346610,"derivative":{"underlying":"Common Stock","underlying_shares":346610},"source":{"system":"sec-edgar","filing":"0001062822-26-000024","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000024/form4.xml","form_type":"4"}},{"id":901910,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63543,"kind":"person","name":"Gopinathan Suma","position":1,"cik":"0002071581","reported_name":"Gopinathan Suma","relationship":{"officer":true,"officer_title":"SVP, Discovery"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-17T21:08:42.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":357680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":357680,"derivative":{"exercise_price":1.37,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":357680},"source":{"system":"sec-edgar","filing":"0001062822-26-000023","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000023/form4.xml","form_type":"4"}},{"id":901909,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63543,"kind":"person","name":"Gopinathan Suma","position":1,"cik":"0002071581","reported_name":"Gopinathan Suma","relationship":{"officer":true,"officer_title":"SVP, Discovery"}}],"security":"Restricted Stock Units","published_at":"2026-02-17T21:08:42.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":238450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":238450,"derivative":{"underlying":"Common Stock","underlying_shares":238450},"source":{"system":"sec-edgar","filing":"0001062822-26-000023","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000023/form4.xml","form_type":"4"}},{"id":901908,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63544,"kind":"person","name":"DeFrancesco Lisa","position":1,"cik":"0001846325","reported_name":"DeFrancesco Lisa","relationship":{"officer":true,"officer_title":"SVP, IR and Corp Comm"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-17T21:07:59.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":386300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":386300,"derivative":{"exercise_price":1.37,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":386300},"source":{"system":"sec-edgar","filing":"0001062822-26-000022","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000022/form4.xml","form_type":"4"}},{"id":901907,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63544,"kind":"person","name":"DeFrancesco Lisa","position":1,"cik":"0001846325","reported_name":"DeFrancesco Lisa","relationship":{"officer":true,"officer_title":"SVP, IR and Corp Comm"}}],"security":"Restricted Stock Units","published_at":"2026-02-17T21:07:59.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":257530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":257530,"derivative":{"underlying":"Common Stock","underlying_shares":257530},"source":{"system":"sec-edgar","filing":"0001062822-26-000022","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000022/form4.xml","form_type":"4"}},{"id":901906,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63542,"kind":"person","name":"Crum Brian T","position":1,"cik":"0001792747","reported_name":"Crum Brian T","relationship":{"officer":true,"officer_title":"SVP, General Counsel & Secr."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-17T21:07:09.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":449560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":449560,"derivative":{"exercise_price":1.37,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":449560},"source":{"system":"sec-edgar","filing":"0001062822-26-000021","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000021/form4.xml","form_type":"4"}},{"id":901905,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63542,"kind":"person","name":"Crum Brian T","position":1,"cik":"0001792747","reported_name":"Crum Brian T","relationship":{"officer":true,"officer_title":"SVP, General Counsel & Secr."}}],"security":"Restricted Stock Units","published_at":"2026-02-17T21:07:09.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":299710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":299710,"derivative":{"underlying":"Common Stock","underlying_shares":299710},"source":{"system":"sec-edgar","filing":"0001062822-26-000021","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000021/form4.xml","form_type":"4"}},{"id":901904,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-17T21:06:19.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":409020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":409020,"derivative":{"exercise_price":1.37,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":409020},"source":{"system":"sec-edgar","filing":"0001062822-26-000020","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000020/form4.xml","form_type":"4"}},{"id":901903,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-17T21:06:19.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":272680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":272680,"derivative":{"underlying":"Common Stock","underlying_shares":272680},"source":{"system":"sec-edgar","filing":"0001062822-26-000020","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000020/form4.xml","form_type":"4"}},{"id":901902,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63540,"kind":"person","name":"Exton Michael","position":1,"cik":"0002029249","reported_name":"Exton Michael","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-17T21:05:31.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":1293670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":1293670,"derivative":{"exercise_price":1.37,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":1293670},"source":{"system":"sec-edgar","filing":"0001062822-26-000019","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000019/form4.xml","form_type":"4"}},{"id":901901,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63540,"kind":"person","name":"Exton Michael","position":1,"cik":"0002029249","reported_name":"Exton Michael","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-17T21:05:31.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":862440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":862440,"derivative":{"underlying":"Common Stock","underlying_shares":862440},"source":{"system":"sec-edgar","filing":"0001062822-26-000019","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000019/form4.xml","form_type":"4"}},{"id":919977,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":1,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":2,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37420,"kind":"person","name":"Artal Participations S.a r.l.","position":4,"cik":"0002048403","reported_name":"Artal Participations S.a r.l.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37421,"kind":"person","name":"Artal International S.C.A.","position":5,"cik":"0001218180","reported_name":"Artal International S.C.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37422,"kind":"person","name":"Artal International Management S.A.","position":6,"cik":"0001522131","reported_name":"Artal International Management S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37423,"kind":"person","name":"Artal Group S.A.","position":7,"cik":"0001053906","reported_name":"Artal Group S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37424,"kind":"person","name":"Westend S.A.","position":8,"cik":"0001283968","reported_name":"Westend S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37425,"kind":"person","name":"Stichting Administratiekantoor Westend","position":9,"cik":"0001460840","reported_name":"Stichting Administratiekantoor Westend","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2026-02-04T21:25:05.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":367145.12,"price":65,"value":23864432.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On January 29, 2026, Artal Participations S.a r.l. entered into a preferred stock purchase agreement (the \"Preferred Purchase Agreement\") with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 367,145.12 shares of Series B Convertible Preferred Stock, par value $0.01 per share (the \"Preferred Stock\") of the Issuer at a price of $65.00 per share. The Preferred Purchase Agreement also provides Artal Participations S.a r.l. the right to purchase from the Issuer, up to an additional 94,854.88 shares of Preferred Stock at a price per share of $65.00. Each share of Preferred Stock will automatically convert into 50 shares of the Issuer's Common Stock upon receipt of shareholder approval and the satisfaction of certain other conditions; however, absent the satisfaction of such conditions, the shares are not convertible. The purchase closed on February 2, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly held by Artal Participations S.a r.l."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the \"Stichting\"). Mr. Amaury Wittouck is the sole member of the board of the Stichting."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":367145.12,"source":{"system":"sec-edgar","filing":"0001193125-26-037644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526037644/ownership.xml","form_type":"4"}},{"id":919976,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":1,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":2,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37420,"kind":"person","name":"Artal Participations S.a r.l.","position":4,"cik":"0002048403","reported_name":"Artal Participations S.a r.l.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37421,"kind":"person","name":"Artal International S.C.A.","position":5,"cik":"0001218180","reported_name":"Artal International S.C.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37422,"kind":"person","name":"Artal International Management S.A.","position":6,"cik":"0001522131","reported_name":"Artal International Management S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37423,"kind":"person","name":"Artal Group S.A.","position":7,"cik":"0001053906","reported_name":"Artal Group S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37424,"kind":"person","name":"Westend S.A.","position":8,"cik":"0001283968","reported_name":"Westend S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37425,"kind":"person","name":"Stichting Administratiekantoor Westend","position":9,"cik":"0001460840","reported_name":"Stichting Administratiekantoor Westend","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-04T21:25:05.000Z","date":"2026-02-02","kind":"purchase","planned":false,"acquired":true,"shares":1538462,"price":1.3,"value":2000000.6,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 2, 2026, Avicenna Life Sci Master Fund LP purchased 1,538,462 shares of Common Stock as part of the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are directly held by Avicenna Life Sci Master Fund LP"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The general partner of Avicenna Life Sci Master Fund LP is Avicenna Life Sci Master GP LLC. The managing member of Avicenna Life Sci Master GP LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":1538462,"source":{"system":"sec-edgar","filing":"0001193125-26-037644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526037644/ownership.xml","form_type":"4"}},{"id":919975,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":1,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":2,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37420,"kind":"person","name":"Artal Participations S.a r.l.","position":4,"cik":"0002048403","reported_name":"Artal Participations S.a r.l.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37421,"kind":"person","name":"Artal International S.C.A.","position":5,"cik":"0001218180","reported_name":"Artal International S.C.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37422,"kind":"person","name":"Artal International Management S.A.","position":6,"cik":"0001522131","reported_name":"Artal International Management S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37423,"kind":"person","name":"Artal Group S.A.","position":7,"cik":"0001053906","reported_name":"Artal Group S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37424,"kind":"person","name":"Westend S.A.","position":8,"cik":"0001283968","reported_name":"Westend S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37425,"kind":"person","name":"Stichting Administratiekantoor Westend","position":9,"cik":"0001460840","reported_name":"Stichting Administratiekantoor Westend","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-04T21:25:05.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":3846154,"price":1.3,"value":5000000.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 29, 2026, Artal Participations S.a r.l. entered into a purchase agreement with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 22,400,000 shares of common stock par value $0.001 per share (the \"Common Stock\") of the Issuer at a price of $1.30 per share (the \"Purchase Price\"). On January 30, 2026, Artal Participations S.a r.l. assigned its right to purchase from the Issuer 3,846,154 shares of Issuer Common Stock to Invus Public Equities, L.P., and Invus Public Equities, L.P. agreed to purchase directly from the Issuer 3,846,154 shares of Issuer Common Stock at the Purchase Price. The purchase closed on February 2, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are directly held by Invus Public Equities, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":7362368,"source":{"system":"sec-edgar","filing":"0001193125-26-037644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526037644/ownership.xml","form_type":"4"}}],"next_cursor":"2026-02-04T21:25:05.000000Z,919975"}